Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH-200 (nelivaptan) in Major Depressive Disorder
2024-513104-34-00Phase 2Completed
- Sponsor
- HMNC Brain Health
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing BH-200 (nelivaptan) 250 mg BID with Placebo (2 arms). Primary endpoint: Change in HAMD-17 total score from baseline to visit 7. Started Sep 2024; status: completed.
02
Drugs
nelivaptan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-513104-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513104-34-00.